Why the study?
Do renin-angiotensin system blockers prevent the development of type 2 diabetes mellitus in high-risk patients?
Do renin-angiotensin system blockers prevent the development of type 2 diabetes mellitus in high-risk patients?
RAS blockers may be considered a suitable therapeutic choice for preventing the development of frank diabetes in high-risk patients with prediabetes conditions.
RAS agents may aid diabetes prevention in prediabetes; leaves open cardiovascular endpoint effects in prospective trials.
Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease (CVD) morbidity and mortality worldwide. Renin-angiotensin system (RAS) blockers have been indispensable in diminishing the macrovascular and microvascular complications of diabetes. In addition, cumulative evidence from retrospective studies pointed toward a beneficial effect of RAS agents in preventing the development and progression of T2DM. This disease-modifying potential of RAS blockers has been substantiated by recent prospective trials. Contemporary concepts regarding the natural history of T2DM and the pathophysiologic processes involved have increased our understanding of the mechanisms underlying the therapeutic potential of these agents in diabetes management. In addition to their established roles in the primary prevention of CVD in patients with diabetes, RAS blockers might be considered a suitable therapeutic choice for preventing the development of frank diabetes in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Lardizabal et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: